Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
3(100.0%)
3Total
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04062058Phase 2Unknown

A Phase II Study of Total Neoadjuvant Therapy for Locally Advanced Gastric Cancer

Role: lead

NCT04664504Phase 2Unknown

A Prospective Phase II Study of Individualized Neoadjuvant Chemoradiotherapy for Rectal Cancer Based on Recurrence Risk

Role: lead

NCT02909114Phase 2Unknown

Stereotactic Body Radiotherapy for Oligometastases From Colorectal Cancer

Role: lead

All 3 trials loaded